Oscar Health (OSCR) Expected to Post Quarterly Earnings on Thursday

Oscar Health (NYSE:OSCR) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Oscar Health to announce earnings of $0.4026 per share and revenue of $4.7301 billion for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.96. Oscar Health had a negative return on equity of 3.26% and a negative net margin of 0.30%.The company had revenue of $4.65 billion for the quarter, compared to the consensus estimate of $4.90 billion. During the same period in the previous year, the business earned $0.92 EPS. The firm’s revenue was up 52.6% compared to the same quarter last year. On average, analysts expect Oscar Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Oscar Health Stock Down 1.6%

Shares of Oscar Health stock opened at $30.74 on Tuesday. The stock’s 50-day moving average is $28.40 and its 200 day moving average is $20.06. Oscar Health has a one year low of $10.69 and a one year high of $33.10. The firm has a market cap of $9.27 billion, a price-to-earnings ratio of -52.09, a PEG ratio of 1.64 and a beta of 2.36. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.11 and a quick ratio of 1.11.

Insider Buying and Selling

In related news, Director Mario Schlosser sold 880,000 shares of Oscar Health stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $29.38, for a total transaction of $25,854,400.00. Following the transaction, the director owned 480,866 shares of the company’s stock, valued at $14,127,843.08. The trade was a 64.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Mark T. Bertolini sold 624,244 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $28.48, for a total value of $17,778,469.12. Following the sale, the chief executive officer owned 7,751,570 shares of the company’s stock, valued at $220,764,713.60. This trade represents a 7.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 3,662,466 shares of company stock worth $105,145,815 over the last three months. Company insiders own 22.64% of the company’s stock.

Institutional Trading of Oscar Health

Institutional investors have recently made changes to their positions in the company. Quarry LP boosted its holdings in Oscar Health by 439.8% during the third quarter. Quarry LP now owns 1,803 shares of the company’s stock worth $34,000 after purchasing an additional 1,469 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after buying an additional 2,242 shares during the last quarter. Strs Ohio purchased a new stake in Oscar Health in the 1st quarter valued at about $30,000. Binnacle Investments Inc bought a new position in shares of Oscar Health during the 2nd quarter worth approximately $75,000. Finally, National Bank of Canada FI bought a new position in shares of Oscar Health during the 3rd quarter worth approximately $81,000. Institutional investors own 75.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Zacks Research raised Oscar Health from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 6th. Barclays raised shares of Oscar Health from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $30.00 to $35.00 in a research report on Wednesday, June 10th. Wells Fargo & Company set a $20.00 price objective on shares of Oscar Health and gave the company an “equal weight” rating in a research note on Thursday, June 4th. Wall Street Zen upgraded shares of Oscar Health from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 14th. Finally, Robert W. Baird increased their target price on shares of Oscar Health from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oscar Health has an average rating of “Hold” and a consensus target price of $22.00.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.